News Feature

Bispecific antibodies and ADCs battle for the limelight, CAR-T therapy sees late surge and China’s growth continues.

Investment continues as the field awaits phase 3 readouts for next-generation radioligand therapies in 2026.

T cell therapies for solid tumors took center stage, while new small-molecule drugs now offer targeted options for hard-to-treat cancers.

AI promises to create medicines faster, more cheaply, and with greater precision. Despite attracting big sums and splashy headlines, AI-powered biotechs have yet to get a product over the finish line. Where is AI’s greatest impact so far?

Bispecific T cell engagers and antibody–drug conjugates took center stage in a year that also brought several new kinds of small-molecule therapies.

From halted healthcare services and corrupted code to stolen personal data held for ransom, cyberwarfare knows no boundaries. Healthcare providers are now facing unprecedented challenges from hackers, with uncertain consequences to patients with cancer.

Three years after the pandemic began, COVID-19 is here to stay. Yet the effects of COVID-19 on cancer research are still unravelling.

From the first engineered T cell receptor medicine to regulatory snubs over China-only data, 2022 was another action-packed year for the oncology drug development community.

From a first-in-class KRAS approval to the latest agonist antibody failures, 2021 was another busy year for cancer drug developers.

Despite widespread vaccination, patients with cancer still face a slew of pandemic-related challenges.

Beyond the suffering caused by the disease, most patients diagnosed with cancer in the USA face substantial financial hardships associated with their treatments. What underlies the financial toxicity of cancer?